A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)

Trial Profile

A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors BerGenBio
  • Most Recent Events

    • 05 Jun 2018 Results assessing identification of predictive and pharmacodynamic biomarkers from NCT02488408, NCT03184571, NCT03184558 NCT02872259, NCT02424617 and NCT02922777 trials presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2018 According to a BerGenBio media release, updated data will be presented throughout 2018.
    • 03 Jun 2018 According to a BerGenBio media release, preliminary data from this study were presented at the American Society of Clinical Oncology Annual Meeting 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top